JimC
Posts:2753

In today's ASCO 2013 video, Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

You can view the video here: http://cancergrace.org/lung/2013/07/03/mek-inhibitor-update-asco-2013/

We welcome your questions and comments here.

JimC
Forum moderator

Discussion Topic
Full Archive
Previous PostNext Post